Back to today’s briefing

Story perspectives

Abivax Poised for $23 Billion Acquisition Amid Trial Success

1/10/2026

31 4

Summary

Story summary

Analysts expect Abivax, the French biotech firm, to be acquired in a deal potentially worth $23 billion after positive trial results for obefazimod.
Abivax shares rose 1,681% in 2025.
Analysts say a large pharmaceutical company may acquire Abivax to bolster its immunology portfolio.
Rumors of interest from Eli Lilly and Company have fueled takeover speculation ahead of the JP Morgan Healthcare Conference.

1 of 1

Story summary

Analysts expect Abivax, the French biotech firm, to be acquired in a deal potentially worth $23 billion after positive trial results for obefazimod.
Abivax shares rose 1,681% in 2025.
Analysts say a large pharmaceutical company may acquire Abivax to bolster its immunology portfolio.
Rumors of interest from Eli Lilly and Company have fueled takeover speculation ahead of the JP Morgan Healthcare Conference.